Organization
Elevar Therapeutics
3 clinical trials
2 abstracts
Clinical trial
An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic CancerStatus: Completed, Estimated PCD: 2020-10-28
Clinical trial
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of OriginStatus: Completed, Estimated PCD: 2023-06-28
Clinical trial
Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal CancerStatus: Terminated, Estimated PCD: 2023-05-31
Abstract
Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, University of Colorado Health Science Center, University of California Los Angeles,
Abstract
Phase 1, randomized, open-label, single-dose, crossover study to evaluate the bioequivalence of four formulations of oral rivoceranib tablets in healthy subjects.Org: Celerion Inc, Tempe, AZ, Elevar Therapeutics, Salt Lake City, UT, Elevar Therapeutics, Inc.,